newsfilter
← Latest News
Business Wire·

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 months Results Presented at AUA 2026 AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood